Cassava Sciences had lengthy claimed that its experimental remedy for Alzheimer’s illness was able to bettering the cognition of sufferers — a profit no different Alzheimer’s drug has ever proven.
However mid-stage examine outcomes up to date on Tuesday now present the cognitive standing of sufferers worsening to the purpose the place Cassava’s drug, referred to as simufilam, doesn’t look any more practical than a placebo.
Proceed to STAT+ to learn the complete story…
